To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@mail.nih.gov along with the following information:

Your name, title, and organization
Study Number and Study Title
The specific dataset(s) you are requesting
The intended use or purpose of the data
Willingness to comply with the NIDA Datashare Registration Agreement

Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-CTN-0028

Division

CTN

HEAL Study

Investigator(s)

Paula Riggs, M.D.

Title

Osmotic-Release Methylphenidate (OROS-MPH) for ADHD in Adolescents with Substance Use Disorders

Short Description

The main study objective was to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.

Release Date

Oct 04, 2010

Description

Research shows a high prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents with substance abuse disorders and indicates that they have poorer substance use treatment outcomes and poorer prognosis and risk of persistence and progression of drug use and behavior problems into adulthood. Although research indicates that the majority are not treated for ADHD while in substance treatment, we do not know whether concurrent pharmacotherapy for ADHD will improve treatment outcomes.

Keywords

adolescent

adhd

oros-mph

Assessments

Adult ADHD Self Report Rating Scale

Child Health Questionnaire

Clinical Global Impression Scales

Composite International Diagnostic Interview for DSM-IV

DSM IV Criteria Substance Related Disorders

DSM-IV ADHD Symptom Checklist

MGH Diversion Questionnaire